WENDER JOSEPH H
Known title: DirectorCIK: 0001073384
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
OUTFRONT Media: No specific company news found. The provided news articles discuss Equinix and Extra Space Storage, not OUTFRONT Media. Therefore, no specific recent developments or announcements for OUTFRONT Media are available in this dataset. The technical data shows the stock is trading near its 52-week high range, with an RSI of 53.8 indicating neutral momentum.
Transaction History
| IONS | ▼ Sell | Open Market | 20,571 | $1.7M | 12/1/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 7,429 | $603K | 12/1/2025 | View on chart |
| IONS | ▲ Buy | Option Exercise | 16,000 | $391K | 11/18/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 11,200 | $842K | 10/31/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 2,484 | $179K | 10/30/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 8,341 | $610K | 10/30/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 5,975 | $441K | 10/30/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 16,800 | $1.1M | 10/1/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 11,200 | $674K | 9/3/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 11,200 | $674K | 9/3/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 11,200 | $616K | 9/2/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 5,600 | $322K | 9/2/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 5,600 | $322K | 9/2/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 11,200 | $616K | 9/2/2025 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,079 | $0 | 7/15/2025 | View on chart |
| OUT | ▲ Buy | Option Exercise | 10,125 | $0 | 6/3/2025 | View on chart |
| OUT | ▲ Buy | Grant | 771 | $0 | 6/3/2025 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,677 | $0 | 7/15/2024 | View on chart |
| OUT | ▲ Buy | Option Exercise | 9,863 | $0 | 6/6/2024 | View on chart |
| OUT | ▲ Buy | Grant | 624 | $0 | 6/6/2024 | View on chart |
| IONS | ▲ Buy | Option Exercise | 16,000 | $568K | 5/9/2024 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/17/2023 | View on chart |
| OUT | ▲ Buy | Option Exercise | 7,290 | $0 | 6/7/2023 | View on chart |
| OUT | ▲ Buy | Grant | 576 | $0 | 6/7/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 2,665 | $0 | 7/15/2022 | View on chart |
| OUT | ▲ Buy | Option Exercise | 4,907 | $0 | 6/8/2022 | View on chart |
| OUT | ▲ Buy | Grant | 201 | $0 | 6/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cathie Wood adds to Ionis position amid RNA sector interest
Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.
Cathie Wood adds to Ionis position amid RNA sector interest. Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.